Abstract

Recurrent respiratory papillomatosis (RRP) is a benign, often multi-focal neoplasm.¹ A potentially fatal manifestation of human papilloma virus infection, the condition is characterised by multiple warty excrescences on the mucosal surface of the respiratory tract. RRP is rare—incidence is estimated at 3.5 per million person-years,² with a prevalence of 4 in 100 000 children. Affected children usually require multiple interventions; the impact on patients, their families, and the healthcare system is considerable. Treatment of RRP accounts for an estimated $109 million annual expenditure in the USA.²